SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

13 Aug 2025 Evaluate
The topline surged 85.59% to Rs. 18.67 millions for the June 2025 quarter as against Rs. 10.06 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2025 is Rs. -147.78 millions as compared to Net Loss of Rs. -76.66 millions of corresponding quarter ended June 2024 Operating profit Margin for the quarter ended June 2025 further decreased to -134.10% as compared to -61.57% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 18.67 10.06 85.59 18.67 10.06 85.59 66.56 116.93 -43.08
Other Income 5.89 39.31 -85.02 5.89 39.31 -85.02 107.26 211.30 -49.24
PBIDT -134.10 -61.57 117.80 -134.10 -61.57 117.80 -412.11 -98.07 320.22
Interest 0.00 0.23 0.00 0.00 0.23 0.00 0.47 1.58 -70.25
PBDT -134.10 -61.80 116.99 -134.10 -61.80 116.99 -412.58 -25.08 1545.06
Depreciation 13.68 14.86 -7.94 13.68 14.86 -7.94 58.22 65.02 -10.46
PBT -147.78 -76.66 92.77 -147.78 -76.66 92.77 -470.80 -90.10 422.53
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.02 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -147.78 -76.66 92.77 -147.78 -76.66 92.77 -470.80 -80.08 487.91
Equity 218.07 218.07 0.00 218.07 218.07 0.00 218.07 218.07 0.00
PBIDTM(%) -718.26 -612.03 17.36 -718.26 -612.03 17.36 -619.16 -83.87 638.23

Suven Life Sciences Share Price

190.40 -4.25 (-2.18%)
13-Apr-2026 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.00
Cipla 1212.95
Zydus Lifesciences 920.00
Lupin 2316.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×